A new research report from Milliman, commissioned by the Leukemia and Lymphoma Society (LLS), found that fewer than half of patients with blood cancer received treatment within 3 months of diagnosis, and LLS says that costs may be keeping patients from getting care.
A new research report from Milliman, commissioned by the Leukemia and Lymphoma Society (LLS), found that fewer than half of patients with blood cancer received treatment within 3 months of diagnosis, and LLS says that costs may be keeping patients from getting care.
The report used CMS data and Medicare Advantage (MA) data to identify patients with newly diagnosed blood cancers, including acute leukemia, chronic leukemia, lymphoma, multiple myeloma, and bone marrow disorders. The researchers identified 35,877 patients who were fee-for-service (FFS) Medicare beneficiaries, and 1898 who had MA plans with Part D coverage (MAPD).
The data showed that, for patients newly diagnosed with blood cancer, only 45% of the MAPD population and 41% of the FFS population received active treatment for their blood cancer within 90 days of their diagnosis. The lowest rates of active treatment were among patients with bone marrow disorders (15% in MAPD and 19% in FFS), while rates were higher among those with multiple myeloma (58% in MAPD and 59% in FFS).
A key driver of spending in blood cancer is anticancer therapy; anticancer products were responsible for 53% ($72,692) of FFS and 55% ($64,968) of MAPD average allowed spending in the first year after diagnosis, and spending in Part B was significantly higher than in Part D in the first year, at $53,524 versus $19,167 (FFS) and $49,375 versus $15,593 (MAPD) average allowed spending.
Those costs also drove high out-of-pocket (OOP) responsibilities for patients; among those patients who did receive active treatment for their cancer, average OOP costs for years 1 and 2 were $17,084 and $8,295, respectively, for FFS patients and $6,896 and $2,603, respectively, for MAPD patients. Some patients had even higher costs; at the 90th percentile for patients with chronic leukemia, FFS patients had average OOP costs of $14,899 in Part B and $10,076 in Part D, and MAPD patients had average OOP costs of $8,942 in Part B and $2,652 in Part D.
Compounding the problem of high OOP spending for FFS beneficiaries is the fact that supplemental insurance, Medigap, can be refused in most states to patients with pre-existing conditions, including cancer.
Taken together, says the LLS, these findings suggest that cost may be a key factor in patients’ decisions to delay or even forego care.
“In addition to the emotional impact of dealing with a blood cancer, patients and families often face extraordinary costs in the first year after diagnosis and beyond,” says Louis J. DeGennaro, PhD, president and chief executive officer of LLS. “The Leukemia and Lymphoma Society hopes that the findings from this new study will prompt payers, providers, patient advocates and policymakers to work together to address the financial burdens for patients.”
LLS urges patients to consider their options closely during the Medicare open enrollment period, which closes on December 7. If enrollees have or expect to have high costs, they may benefit from an MA plan with options that feature OOP caps.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
HLX02, Pertuzumab, Chemotherapy Combination Effective, Safe in Advanced HER2-Positive Breast Cancer
March 12th 2024A study found combining trastuzumab biosimilar HLX02, pertuzumab, and chemotherapy was effective and safe for patients with HER2-positive metastatic breast cancer who progressed after prior trastuzumab therapy.
The Role of Biosimilars: Advancing Access, Financial Health, and System Sustainability
March 11th 2024Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care, a member of the Community Oncology Alliance, and member of The Center for Biosimilars® Advisory Board, glances back at the development of the biosimilar industry and the last 5 years of progress.